These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8830885)

  • 21. The glucagon-like peptides: a double-edged therapeutic sword?
    Perry T; Greig NH
    Trends Pharmacol Sci; 2003 Jul; 24(7):377-83. PubMed ID: 12871671
    [No Abstract]   [Full Text] [Related]  

  • 22. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.
    Sarrauste de Menthière C; Chavanieu A; Grassy G; Dalle S; Salazar G; Kervran A; Pfeiffer B; Renard P; Delagrange P; Manechez D; Bakes D; Ktorza A; Calas B
    Eur J Med Chem; 2004 Jun; 39(6):473-80. PubMed ID: 15183905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The human glucagon-like peptide-1 (GLP-1) receptor. Cloning and functional expression.
    Dillon JS; Wheeler MB; Leng XH; Ligon BB; Boyd AE
    Adv Exp Med Biol; 1997; 426():113-9. PubMed ID: 9544263
    [No Abstract]   [Full Text] [Related]  

  • 24. Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands.
    Uttenthal LO; Blázquez E
    FEBS Lett; 1990 Mar; 262(1):139-41. PubMed ID: 2156728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge.
    López de Maturana R; Donnelly D
    FEBS Lett; 2002 Oct; 530(1-3):244-8. PubMed ID: 12387900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function.
    Van Eyll B; Göke B; Wilmen A; Göke R
    Peptides; 1996; 17(4):565-70. PubMed ID: 8804062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action.
    Hareter A; Hoffmann E; Bode HP; Göke B; Göke R
    Endocr J; 1997 Oct; 44(5):701-5. PubMed ID: 9466326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.
    Plamboeck A; Holst JJ; Carr RD; Deacon CF
    Adv Exp Med Biol; 2003; 524():303-12. PubMed ID: 12675252
    [No Abstract]   [Full Text] [Related]  

  • 29. Learning from the gut.
    Mattson MP; Perry T; Greig NH
    Nat Med; 2003 Sep; 9(9):1113-5. PubMed ID: 12949521
    [No Abstract]   [Full Text] [Related]  

  • 30. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.
    Scrocchi LA; Brown TJ; MaClusky N; Brubaker PL; Auerbach AB; Joyner AL; Drucker DJ
    Nat Med; 1996 Nov; 2(11):1254-8. PubMed ID: 8898756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central glucagon-like peptide-I in the control of feeding.
    Gunn I; O'Shea D; Turton MD; Beak SA; Bloom SR
    Biochem Soc Trans; 1996 May; 24(2):581-4. PubMed ID: 8736807
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeted gene disruption in endocrine research--the case of glucagon-like peptide-1 and neuroendocrine function.
    Seeley RJ; Woods SC; D'Alessio D
    Endocrinology; 2000 Feb; 141(2):473-5. PubMed ID: 10650925
    [No Abstract]   [Full Text] [Related]  

  • 33. Dietary interventions in noninsulin-dependent diabetes mellitus: new approaches.
    Woods SC; Seeley RJ
    Nutrition; 1998 Jun; 14(6):527-8. PubMed ID: 9646296
    [No Abstract]   [Full Text] [Related]  

  • 34. A target cell to oxyntomodulin and glicentin: the antral smooth muscle cell.
    Rodier G; Magous R; Mochizuki T; Bali JP; Bataille D; Jarrousse C
    Ann N Y Acad Sci; 1998 Dec; 865():458-62. PubMed ID: 9928049
    [No Abstract]   [Full Text] [Related]  

  • 35. Hindbrain contributions to anorexia.
    Rinaman L
    Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1035-6. PubMed ID: 15475502
    [No Abstract]   [Full Text] [Related]  

  • 36. [Targeting--a new way to identify unknown tumor markers in blood vessels].
    Wallin E; Akerman ME; Palmblad J
    Lakartidningen; 2005 Feb 21-27; 102(8):551-2, 554-5. PubMed ID: 15786906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Three Ds of Transcription Activation by Glucagon: Direct, Delayed, and Dynamic.
    Goldstein I; Hager GL
    Endocrinology; 2018 Jan; 159(1):206-216. PubMed ID: 29077799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon receptor signalling - backwards and forwards.
    Wu T; Rayner CK; Marathe CS; Jones KL; Horowitz M
    Expert Opin Investig Drugs; 2018 Feb; 27(2):135-138. PubMed ID: 29333878
    [No Abstract]   [Full Text] [Related]  

  • 39. Endo-neuro-endocrine incretin pathways.
    Cupples WA
    Am J Physiol Regul Integr Comp Physiol; 2004 Feb; 286(2):R250. PubMed ID: 14707009
    [No Abstract]   [Full Text] [Related]  

  • 40. A glucagon analogue decreases body weight in mice via signalling in the liver.
    Hinds CE; Owen BM; Hope DCD; Pickford P; Jones B; Tan TM; Minnion JS; Bloom SR
    Sci Rep; 2021 Nov; 11(1):22577. PubMed ID: 34799628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.